Psoriatic onychodystrophy is a comorbidity that often occurs in patients with psoriasis, affecting their quality of life. Although success has recently been achieved in the treatment of the cutaneous form of psoriasis, there are few publications about nail therapy with proven effectiveness. The development of effective and safe therapies remains relevant for nail psoriasis. Objective. to evaluate the effectiveness and tolerability of the fixed combination of betamethasone dipropionate 0.05%/calcipotriol monohydrate 0.005% gel and clobetasole propionate 0.05% ointment in patients with psoriatic onychodystrophy. Material and methods. the study included 50 patients with psoriasis vulgaris, mild to moderate severity with lesions of the nail plates. Patients were divided into two groups and used betamethasone dipropionate 0.05%/calcipotriol monohydrate 0.005% gel (group A) and clobetasole propionate 0.05% ointment with occlusion (group B) for 24 weeks with hardware treatment of nail plates at 0, 8, 16 weeks. They did not receive any other local or systemic treatment. The severity of nail psoriasis was assessed by the NAPSI index at week 0, 8, 16, and 24, and by the IGA after treatment. results. 43 patients completed the study. At the beginning of the study, the average NAPSI was 32.8 ± 10.3 in group A and 33.1 ± 9.8 in group B. At week 24 the average NAPSI score decreased to 12.8 ± 7.2 in group A and 11.8 ± 68 in group B. IGA for evaluation treatment score was 3 ± 0.74 in group A and 3.1 ± 0.79 in group B. Conclusions. Combined treatments in the form of hardware processing nail plates with betamethasone dipropionate 0.05%/calcipotriol monohydrate 0.005% gel and clobetasol propionate 0.05% ointment are effective and can be used in patients with moderate and severe nail psoriasis, which is confirmed by the results in clinical improvement of 60.8% and 64.5%, respectively, based on a decrease in NAPSI at 24 weeks and an assessment of the therapeutic response after treatment using the IGA.